Eksempler på brug af Vertebral fracture på Engelsk og deres oversættelser til Dansk
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
At least one new vertebral fracture 0- 1 year.
These tests may show evidence of herniated disks and vertebral fractures.
No effect on non- vertebral fractures was seen.
Relative Risk Reduction New morphometric vertebral fractures.
Summary of vertebral fracture efficacy at 12, 24 and 36 months.
Would have application to vertebral fractures;
An effect on non- vertebral fractures has nonetheless not been demonstrated in this population.
Reduction(95% CI) vs. placebo New radiographic vertebral fractures.
Incidence of patients with vertebral fracture and relative risk reduction.
Forsteo was more effective than placebo in reducing vertebral fractures.
The incidence of new vertebral fractures was evaluated as a safety variable.
Twenty-eight percent of patients had one or more radiographic vertebral fractures at baseline.
The incidence of clinical vertebral fractures was also significantly reduced by 49% p=0.011.
Pens pensioner, aged 65+ Prov provider, aged 20-64 Vert fr vertebral fracture Incr increase.
Any clinical fracture(1) Clinical vertebral fracture(2) Non-vertebral fracture(1)*p-value< 0.001,**p-value< 0.0001.
These results may have been confounded by baseline differences in BMD and vertebral fractures.
OSSEOR reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study table 1.
A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture.
At baseline, 35% of patients had a vertebral fracture and 59% had a non-vertebral fracture. .
Calcitonin has also been reported to have an analgesic effect in patients with a recent vertebral fracture.
In the 4th year alone, EVISTA reduced the new vertebral fracture risk by 39% RR 0.61, CI 0.43, 0.88.
During a median of 18 months following discontinuation of FORSTEO, there was a 41% reduction(p=0.004)compared with placebo in the number of patients with a minimum of one new vertebral fracture.
Forsteo reduced the risk of developing a new vertebral fracture over 19 months by 65% compared with placebo.
In women with a prevalent vertebral fracture at baseline, FABLYN significantly reduced the incidence of new vertebral radiographic fractures from 14.2% for placebo to 8.7% for FABLYN relative risk reduction 42%, p 0.0004.
In this study alendronate daily reduced the incidence of≥ 1 new vertebral fracture by 47% alendronate 7.9% vs. placebo 15.0.
The natural history of pain after vertebral fracture is extremely variable; in general, there is a slow improvement over time but in some patients, pain or discomfort is a permanent sequel.
In this study alendronate daily reduced the incidence of≥ 1 new vertebral fracture by 47% alendronate 7.9% versus placebo 15.0.
In this study, in a subgroup analysis of osteoporotic women(37% of the total population who fulfilled the definition of osteoporosis given above) a significant difference was seen in the incidence of hip fractures(alendronate 1.0% versus placebo 2.2%, a reduction of 56%) andin the incidence of≥ 1 vertebral fracture 2.9% versus 5.8%, a reduction of 50.
Thereafter, it is assumed that the vertebral fracture incidence will increase at half the rate of the increase in hip fracture incidence.
The risk was reduced by 41% over three years, with 21% of the 719 women who took OSSEOR developing a new vertebral fracture, compared with 33% of those 723 who took placebo.